CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 58 enrolled
Drug / intervention
RSV A Memphis 37biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01349543
NCT01349543N/ACompleted

The Development of a Human Model of Respiratory Syncytial Virus Infection

Imperial College London·interventional·Posted May 6, 2011·Updated Sep 19, 2024

In Brief

A clinical study evaluating RSV A Memphis 37 for Respiratory Syncytial Virus Infections and Respiratory Viral Infections. Completed, enrolled 58 participants across 1 site.

Detailed Summary

The aim of this study is to understand the immune response (how the body fights infection) to Respiratory Syncytial Virus (RSV). This virus usually causes a simple 'common cold' illness in healthy adults, but can cause wheezing and lung problems in young infants and the elderly. The investigators want to understand why this is, in order to develop vaccines and treatments. Participants will include 30-40 healthy adults age 18-55 years. Study procedures will include brief medical exams, breathing tests, a diary of symptoms, blood tests, samples of fluid (lavage) and cells from the nose, throat and lungs. All participants will receive the virus via drops in the nose. The duration of the study for all subjects will be 6 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
CollaboratorsWellcome Trust

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 6, 2011
Enrollment StartMay 1, 2011
Primary CompletionOct 1, 2013
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.2 years ago

Interventions

RSV A Memphis 37biological

Intranasal administration